Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1996-09-17
2000-02-22
Henley, III, Raymond
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514277, 514299, 514342, 514367, 514369, 514370, 514569, 514725, A61K 3828, A61K 31435, A61K 3144, A61K 31425, A61K 3119
Patent
active
060280522
ABSTRACT:
This invention relates to methods and compositions for the treatment of non-insulin-dependent diabetes mellitus using an RXR agonist alone or in combination with a PPAR.gamma. agonist such as a thiazolidinedione compound.
REFERENCES:
patent: 4981784 (1991-01-01), Evans et al.
patent: 4981787 (1991-01-01), Baram
patent: 5071773 (1991-12-01), Evans et al.
patent: 5219888 (1993-06-01), Katocs et al.
patent: 5298429 (1994-03-01), Evans et al.
patent: 5399586 (1995-03-01), Davies et al.
patent: 5455265 (1995-10-01), Chandraratna
patent: 5466861 (1995-11-01), Dawson et al.
patent: 5506102 (1996-04-01), McDonnell
patent: 5594015 (1997-01-01), Kurtz et al.
patent: 5728739 (1998-03-01), Aihaud et al.
patent: 5827897 (1998-10-01), Aihaud et al.
Tontonoz, et al. "MPPAR.gamma.2: tissue-specific regulator of an adipocyte enhancer" Genes & Development 8: 1224-1234 (1994).
Boehm, et al. "Design and Synthesis of Potent X Receptor Selective Ligands that Induce Apoptosis in Leukemia Cells" J. Med. Chem. 38: 3146-3155 (1995).
Lehmann, et al. An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor .gamma. (PPAR.gamma.)*, J. Biol. Chem. 270(22): 12953-12956 (1995).
Safonova, et al. "Fatty Acids and Retinoids Act Synergistically on Adipose Cell Differentiation" Biochem. and Biophysical Research Communications 204(2): 498-504 (1994).
Amri, et al. "Regulation of adipose cell differentiation. I. Fatty acids are inducers of the aP2 gene expression" J. Lipid Research 32: 1449-1456 (1991).
Amri, et al. "Regulation of adipose cell differentiation. II. Kinetics of induction of the aP2 gene by fatty acids and modulation of dexamethasone" J. Lipid Research 32: 1457-1463 (1991).
Antrast, et al. "Adipsin Gene Expression in 3T3-F442A Adipocytes Is Postranscriptionally Down-regulated by Retinoic Acid" J. Biol. Chem. 266(2): 1157-1161 (1991).
Boehm, et al. "Synthesis and Structure-Activity Relationships of Novel Retinoid X Receptor-Selective Retinoids" J. Med. Chem. 37: 2930-2941 (1994).
Boehm, et al. "Design and Synthesis of Potent Retinoid X Receptor Selective Ligands That Induce Apoptosis in Leukemia Cells" J. Med. Chem. 38: 3146-3155 (1995).
Grimaldi, et al. "Induction of aP2 gene expression by nonmetabolized long-chain fatty acids" Proc. Natl. Acad. Sci. USA 89: 10930-10934 (1992).
Kees, et al. "Studies on New Acidic Azoles as Glucose-Lowering Agents in Obese, Diabetic db/db Mice" J. Med. Chem. 38: 617-628 (1995).
Kliewer, et al. "Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors" Nature 358: 771-774 (1992).
Lehmann, et al. An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor .gamma. (PPAR.gamma.)* J. Biol. Chem. 270(22): 12953-12956 (1995).
Mukherjee, et al. "Human and Rat Peroxisome Proliferator Activated Receptors (PPARs) Demonstrate Similar Tissue Distribution but Different Responsiveness to PPAR Activators" J. Steroid Biochem. Molec. Biol. 51(3/4): 157-166 (1994).
Safonova, et al. "Retinoids are positive effectors of adipose cell differentiation" Molecular and Cellular Endocrinology 104: 201-211 (1994).
Salazar-Olivo, et al. "Inhibition of 3T3 Adipogenesis by Retinoic Acid is Not Mediated by Cytoplasmic Retinoic Acid-Binding Protein" Biochemical and Biophysical Research Communications 204(1): 257-263 (1994).
Tontonoz, et al. "Stimulation of Adipogenesis in Fibroblasts by PPAR.gamma.2, a Lipid-Activated Transcription Factor" Cell 79: 1147-1156 (1994).
Willson, et al. "The Structure-Activity Relationship between Peroxisome Proliferator-Activated Receptor .gamma. Agonism and the Antihyperglycemic Activity of Thiazolidinediones" J. Med. Chem. 39: 665-668 (1996).
Young, et al. "Repeat Treatment of Obese Mice With BRL 49653, a New and Potent Insulin Sensitizer, Enhances Insulin Action in White Adipocytes" Diabetes 44: 1087-1092 (1995).
Fingl et al., in The Pharmacological Basis of Therapeutics, 1975, Ch. 1, p. 1.
Cesario Rosemary
Heyman Richard A.
Mukherjee Ranjan
Henley III Raymond
Ligand Pharmaceuticals Incorporated
LandOfFree
Treating NIDDM with RXR agonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treating NIDDM with RXR agonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treating NIDDM with RXR agonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-520574